Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Published:2020-02-16 Issue:8 Volume:9 Page:2621-2630
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Cheng Ying¹^ORCID,Han Baohui²^ORCID,Li Kai³^ORCID,Wang Qiming⁴,Zhang Li⁵,Shi Jianhua⁶,Wang Zhehai⁷,He Jianxing⁸,Shi Yuankai⁹^ORCID,Chen Weiqiang¹⁰,Wang Xiuwen¹¹,Luo Yi¹²,Nan Kejun¹³,Jin Faguang¹⁴,Li Baolan¹⁵,Zhu Jing¹⁶

Affiliation:

1. Jilin Cancer Hospital Changchun China

2. Shanghai Chest Hospital Shanghai Jiaotong University Shanghai China

3. Tianjin Medical University Cancer Hospital Tianjin China

4. Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou China

5. Peking Union Medical College Hospital Beijing China

6. Lin Yi Cancer Hospital Linyi China

7. Shandong Cancer Hospital Jinan China

8. The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

9. Cancer Hospital Chinese Academy of Medical Sciences Beijing China

10. Lanzhou Military General Hospital Lanzhou China

11. Qilu Hospital of Shandong University Jinan China

12. Hunan Cancer Hospital Changsha China

13. The First Affiliated Hospital of Xi'An Jiaotong University Xi'an China

14. Tang Du Hospital Xi'an China

15. Beijing Chest Hospital Capital Medical University Beijing China

16. Jilin Cancer Hospital Jilin China

Funder

Chia-tai Tianqing Pharmaceutical Group Co., Ltd

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2913

Reference33 articles.

1. Global cancer statistics, 2012

2. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

3. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

4. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

5. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer;OncoTargets and Therapy;2024-08

2. Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study;Journal of Thoracic Oncology;2024-08

3. Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study;Cancer Medicine;2024-06

4. Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer;Journal of Gynecologic Oncology;2024

5. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials;Frontiers in Immunology;2023-08-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3